凯普生物(300639.SZ)：2025年三季报净利润为-1.28亿元

Core Insights - The company reported a total operating revenue of 486 million yuan for Q3 2025, ranking 43rd among disclosed peers, which represents a decrease of 124 million yuan or 20.38% year-on-year [1] - The net profit attributable to shareholders was -128 million yuan, ranking 75th among peers [1] - The net cash inflow from operating activities was 121 million yuan [1] Financial Metrics - The latest debt-to-asset ratio is 12.93%, an increase of 2.89 percentage points compared to the same period last year [3] - The latest gross profit margin is 47.56%, ranking 48th among peers, down 6.25 percentage points year-on-year [3] - The latest return on equity (ROE) is -3.32%, ranking 72nd among peers [3] - The diluted earnings per share (EPS) is -0.20 yuan, ranking 70th among peers [3] - The total asset turnover ratio is 0.11 times, ranking 72nd among peers, remaining flat year-on-year but down 3.28% compared to the previous year [3] - The inventory turnover ratio is 3.51 times [3] Shareholder Information - The number of shareholders is 28,200, with the top ten shareholders holding 306 million shares, accounting for 47.41% of the total share capital [3] - The largest shareholder is Hong Kong Science and Technology Venture Capital Co., Ltd., holding 29.8 million shares [3] - Other significant shareholders include Yunnan Zhonghe Enterprise Management Co., Ltd. and Shenzhen Guodiao Investment Fund, holding 6.21 million and 4.76 million shares respectively [3]